This is particularly exciting, as a gene therapy approach for inhibiting SARM1 has recently been shown to be effective in vivo in a model of nerve transection (Geisler et al, 2019), and gene therapy is well suited as a treatment strategy for retinal degeneration evidenced by the fact that the first FDA-approved prescription for gene therapy was for people with inherited retinal disease. The gene discussed is SARM1; the disease is retinal degeneration.